OPKO Health

OPKO Health, Inc. is a biopharmaceutical and diagnostics company, which engages in the provision of healthcare services. It operates through the following segments: Diagnostics and Pharmaceuticals. The Diagnostics segment includes the clinical laboratory operations of BioReference, as well as point-of-care operations. The Pharmaceuticals segment includes pharmaceutical operations in Chile, Mexico, Ireland, Israel, and Spain and pharmaceutical research and development operations. The company was founded in October 1991 and is headquartered in Miami, FL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

OPKO Health reports robust Q4 performance and outlines growth strategies

OPKO Health's Q4 2022 earnings call highlighted positive performance, innovative strengths, challenges in market positioning, and opportunities for growth and profitability.
The company's focus on product development, operational efficiencies, and strategic clarity underscores a commitment to driving shareholder value and market leadership.
Analyst inquiries and management responses showcased transparency, strategic foresight, and a proactive approach to addressing market dynamics and regulatory challenges.

OPKO Health reports Q1 revenue growth, strategic partnerships with Merck

OPKO Health's Q1 2023 performance reflects revenue growth in Pharmaceuticals but challenges in Diagnostics segment revenue.
Strengths lie in strategic partnerships with Merck, diversified growth initiatives, and cost-saving measures.
Challenges include limited disclosure on NGENLA approval and revenue recognition complexities.
Opportunities exist in new revenue streams, specialty testing expansion, and strategic collaborations for future growth.
Overall, OPKO Health's performance showcases a mix of strengths, challenges, and opportunities for strategic growth and market leadership.

OPKO Health reports improved Q2 performance and growth opportunities

OPKO Health's Q2 2023 performance showed improvements in operating income and revenue despite challenges in the Diagnostics segment.
The company's strategic strengths lie in successful product approvals, collaborations with Merck, and revenue diversification efforts.
While facing challenges such as revenue fluctuations and profitability concerns, OPKO Health is poised for growth with promising opportunities ahead.
Overall, OPKO Health's financial outlook remains positive, with a focus on profitability and expansion through strategic initiatives and partnerships.

OPKO Health excels in Q3 with revenue growth and innovation

OPKO Health's Q3 2023 performance showcased revenue growth, strong product offerings, and strategic advancements in healthcare solutions.
The company's strengths include successful products, cost-cutting measures, and a focus on innovation through collaborations and contracts.
Challenges include the need for more detailed financial disclosures and transparent communication on operational metrics.
Amidst challenges, opportunities for growth through product expansion, partnerships, and operational optimization are key focus areas for OPKO Health.

OPKO Health excels in 2023 with strategic partnerships and growth

OPKO Health demonstrated strong performance in 2023 with key achievements and positive growth in sales and collaborations.
While facing challenges such as revenue decline in the Diagnostics segment, the company is actively addressing them through cost reduction efforts.
Strategic partnerships, financial refinancing, and clear guidance for 2024 position OPKO Health for continued success and growth.

OPKO Health sells assets, expands therapies globally for growth

OPKO Health is strategically streamlining operations and expanding globally.
Despite revenue declines, the company is focused on profitability and growth.
Strong progress in ModeX programs and collaborations for new therapies.
Emphasis on oncology testing and potential partnerships in oncology space.

OPKO Health reports robust Q2 performance and eyes growth opportunities

OPKO Health's Q2 2024 earnings call highlighted strong financial performance, strategic initiatives for growth, and a focus on operational efficiency and innovation.
The company faces challenges in managing expectations, addressing concerns, and navigating potential acquisitions, but opportunities in collaborations and market expansion are promising.
Overall, OPKO Health's disciplined approach to financial management, clinical development, and strategic partnerships positions it for continued success and value creation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

OPKO Health (OPK) delivered earnings and revenue surprises of 0.00% and 14.07%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

OPKO Health (OPK) Matches Q3 Earnings Estimates

Shares of OPKO Health (NASDAQ:OPK) fell 6.4% in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share were up 144.44% year over year to $0.04, which were in line with the estimate of $0.04.

OPKO Health: Q3 Earnings Insights

OPKO Health's (OPK) third-quarter results are likely to reflect solid performance from Products segment and RAYALDEE.

OPKO Health (OPK) to Report Q3 Earnings: What's in Store?

OPKO Health's (OPK) BioReference Laboratories' new multiplex test can differentiate between COVID-19 and Influenza infections with a single sample.

OPKO Health's (OPK) BioReference Laboratories Unveils New Test

OPKO Health (OPK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

OPKO Health (OPK) Reports Next Week: Wall Street Expects Earnings Growth

Despite high-profile agreements to provide coronavirus testing, this small-cap company might not pass the test in the long term.

Is OPKO Health Stock a Buy?

BioNTech SE

One is producing large numbers of COVID-19 diagnostic tests; the other may be among the first companies to get a coronavirus vaccine approved.

Better Coronavirus Stock: Opko Health or BioNTech?

QuidelOrtho Corp

Successful partnerships with major sports leagues and updated guidance may mean coronavirus testing is here to stay.

Quidel and OPKO Health Are Scoring With Coronavirus Testing in Sports. Is the Market Missing It?

Pounding The Table For Undervalued OPKO Health

MIAMI, Oct. 13, 2020 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three months ended September 30, 2020, as well as discuss financial guidance, after the close of the U.S. financial markets on Thursday, October 29, 2020. OPKO’s senior management will provide a business update and discuss results in greater detail during a conference call and live audio webcast on October 29th beginning at 4:30 p.m. Eastern time.

OPKO Health to Report Third Quarter 2020 Financial Results on October 29, 2020

ELMWOOD PARK, N.J., Oct. 9, 2020 /PRNewswire/ -- BioReference Laboratories, Inc., an OPKO Health company (NASDAQ :OPK), today announced the beginning of its COVID-19 testing program for New York City schools throughout the 2020-2021 school year to help ensure a safer school environment....

OPKO Health's BioReference Laboratories Launches COVID-19 Testing Program for New York City Schools

SEATTLE, Oct. 8, 2020 /PRNewswire/ -- UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF FLORIDA Case No. 1:18-cv-23786-MARTINEZ-OTAZO-REYES CHARLES STEINBERG, individually and on Behalf of All Others Similarly Situated, Plaintiff, v. OPKO HEALTH, INC., PHILLIP FROST, ADAM LOGAL, and JUAN...

Notice of Class Action Settlement Involving Purchasers of OPKO Health, Inc. Common Stock during the period of September 26, 2013 through September 7, 2018

Pfizer

NEW YORK & MIAMI--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and OPKO Health Inc. (NASDAQ: OPK) announced today that C0311002, a Phase 3, randomized, multicenter, open-label, crossover study evaluating somatrogon dosed once-weekly in children 3 to

Pfizer Announces Positive Phase 3 Top-line Results for Once-Weekly Investigational Long-Acting Human Growth Hormone to Treat Children with Growth Hormone Deficiency

OPKO Health (OPK) closed the most recent trading day at $4.40, moving +1.15% from the previous trading session.

OPKO Health (OPK) Gains But Lags Market: What You Should Know

Market forces favor the drug testing and development company.

Why OPKO Health Jumped 13.9% in September

Investors need to pay close attention to OPKO (OPK) stock based on the movements in the options market lately.

Implied Volatility Surging for OPKO (OPK) Stock Options

Is  (OPK) Outperforming Other Medical Stocks This Year?

Has OPKO Health (OPK) Outpaced Other Medical Stocks This Year?

DaVita

Merit Medical Systems

Backed by projections of robust earnings growth rates,  there are a few MedTech stocks which are ideal for long-term bet.

3 Great MedTech Stocks to Pick Amid the Coronavirus Crisis

OPKO Health (OPK) is developing its marketed drug, Rayaldee, as a potential treatment for patients with mild-to-moderate COVID-19.

OPKO Health Initiates Mid-Stage Study on Coronavirus Therapy

OPKO Health, Inc. (OPK) Presents at H.

MIAMI, Sept.  15, 2020  (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) announces the initiation of a Phase 2 trial with RAYALDEE® as a treatment for mild-to-moderate COVID-19.  The trial, “A Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Safety and Efficacy of  R AYALDEE (calcifediol)  E xtended-relea s e  C aps u l e s to Treat Symptomatic Patients Infected with SARS-CoV-2 ( REsCue ),” is expected to enroll approximately 160 subjects, many with stage 3 or 4 chronic kidney disease (CKD) who are at higher risk for developing more severe illness.

OPKO Health Initiates Clinical Trial of RAYALDEE in COVID-19 Patients

Is OPKO Health (OPK) Outperforming Other Medical Stocks This Year?

Vaxart

Competition from heavy hitters spooked investors.

Why These 3 Coronavirus-Related Stocks Plummeted More Than 35% in August

OPKO Health's (OPK) OnkoSight Advanced is a NGS assay that facilitates revolutionary DNA mutational profiling of tumor samples.

OPKO Health's BioReference Laboratories Introduces NGS Assay

MIAMI, Sept.  02, 2020  (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced that management will be participating in two upcoming virtual investor conferences.

News for OPKO Health Stock (OPK)